BackMarinus Pharmaceuticals Overview

Marinus Pharmaceuticals Other Current Assets

Marinus Pharmaceuticals's other current assets is $4.7M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$4.66M
60.06% YoYΔ $-7.01M vs prior year quarter

Peer average / median

Loading

Marinus Pharmaceuticals Other Current Assets History

Loading

Marinus Pharmaceuticals vs. peers: Other Current Assets Comparison

Loading

Marinus Pharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Marinus Pharmaceuticals (MRNS) FAQ

Marinus Pharmaceuticals (MRNS) currently reports a other current assets of $4.7M as of September 2024. That compares with $12M in the prior-year period — down 60.1% year over year. Use the charts on this page to explore Marinus Pharmaceuticals's other current assets history and peer comparisons.

Marinus Pharmaceuticals's other current assets decreased from $12M to $4.7M — a 60.1% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Marinus Pharmaceuticals reported $4.7M in other current assets as of September 2024. That compares with $12M in the prior-year period — down 60.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $4.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Marinus Pharmaceuticals, and consider following MRNS for alerts when major investors trade the stock.

Marinus Pharmaceuticals is classified in the Healthcare sector. On other current assets, it currently shows $4.7M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MRNS with unrelated industries.